m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00563)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
NUMB
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Treatment: METTL3 knockdown MDA-MB-231 cells
Control: MDA-MB-231 cells
|
GSE70061 | |
Regulation |
|
logFC: 9.75E-01 p-value: 1.24E-03 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 acts as a fate determinant that controls the sensitivity of bladder cancer cells to melittin treatment. Moreover, METTL3/miR-146a-5p/Protein numb homolog (NUMB)/NOTCH2 axis plays an oncogenic role in bladder cancer pathogenesis and could be a potential therapeutic target for recurrent bladder cancer treatment. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Responsed Drug | Melittin | Investigative | ||
Cell Process | miRNA maturation | |||
Cell apoptosis | ||||
In-vitro Model | T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
EJ (Human bladder cancer cells) | ||||
BIU-87 | Human bladder cancer cells | Homo sapiens | CVCL_6881 | |
In-vivo Model | For melittin treatment study, 4-week-old female BALB/c nude mice were subcutaneously injected with 1 × 107 T24 or BIU87 cells. | |||
Bladder cancer [ICD-11: 2C94]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 acts as a fate determinant that controls the sensitivity of bladder cancer cells to melittin treatment. Moreover, METTL3/miR-146a-5p/Protein numb homolog (NUMB)/NOTCH2 axis plays an oncogenic role in bladder cancer pathogenesis and could be a potential therapeutic target for recurrent bladder cancer treatment. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Melittin | Investigative | ||
Cell Process | miRNA maturation | |||
Cell apoptosis | ||||
In-vitro Model | T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
EJ (Human bladder cancer cells) | ||||
BIU-87 | Human bladder cancer cells | Homo sapiens | CVCL_6881 | |
In-vivo Model | For melittin treatment study, 4-week-old female BALB/c nude mice were subcutaneously injected with 1 × 107 T24 or BIU87 cells. | |||
Melittin
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | METTL3 acts as a fate determinant that controls the sensitivity of bladder cancer cells to melittin treatment. Moreover, METTL3/miR-146a-5p/Protein numb homolog (NUMB)/NOTCH2 axis plays an oncogenic role in bladder cancer pathogenesis and could be a potential therapeutic target for recurrent bladder cancer treatment. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Cell Process | miRNA maturation | |||
Cell apoptosis | ||||
In-vitro Model | T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
EJ (Human bladder cancer cells) | ||||
BIU-87 | Human bladder cancer cells | Homo sapiens | CVCL_6881 | |
In-vivo Model | For melittin treatment study, 4-week-old female BALB/c nude mice were subcutaneously injected with 1 × 107 T24 or BIU87 cells. | |||